IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells for Melanoma
Study Summary
This trial is studying the side effects and best dose of genetically modified immune cells, called IL13Ralpha2 CAR T cells, for patients with stage IIIC or IV melanoma.
- Metastatic Melanoma
- Cutaneous Melanoma Stage III
- Asthma-COPD Overlap Syndrome (ACOS)
- Stage IV Cutaneous Melanoma
Treatment Effectiveness
Study Objectives
2 Primary · 10 Secondary · Reporting Duration: Up 2 years
Trial Safety
Trial Design
1 Treatment Group
Treatment (chemotherapy, IL13Ralpha2, Il-2)
1 of 1
Experimental Treatment
24 Total Participants · 1 Treatment Group
Primary Treatment: IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 11 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Is the FDA permitting any clinical application of IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19 Autologous TN/MEM Cells?
"Our team at Power has assessed the safety of IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19 Expressing Autologous TN/MEM Cells to be a 1 due to its status as a Phase 1 study, indicating that there is limited information on both efficacy and safety." - Anonymous Online Contributor
What health issue can be managed with the aid of IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells?
"IL13Ralpha2-specific Hinge-optimized 4-1BB co-stimulatory CAR/Truncated CD19 expressing Autologous TN/MEM Cells are primarily used to manage multiple sclerosis. This therapy can also potentially help patients with leukemia, myelocytic, acute and retinoblastoma histiocytic lymphomas." - Anonymous Online Contributor
What findings have past researchers discovered when utilizing IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19 Autologous TN/MEM Cells?
"Currently, there are 901 clinical trials for IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells with 161 of them in Phase 3. Philadelphia, Pennsylvania has a large number of those studies running within its borders but globally the total is 28476 locations." - Anonymous Online Contributor
What is the cohort size of this particular research endeavor?
"Affirmative, the information provided on clinicaltrials.gov indicates that this research is in its active recruitment phase and began accepting applications as of November 27th 2019. The study seeks 24 participants from two separate trial sites." - Anonymous Online Contributor
Are investigators still enrolling for this research endeavor?
"Affirmative. According to the information hosted on clinicaltrials.gov, this research study is currently looking for volunteers; it was initially posted in November 2019 and modified a few days ago in April 2022. The team is recruiting 24 individuals from two different facilities." - Anonymous Online Contributor